We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals
MIRM

39 hedge funds and large institutions have $398M invested in Mirum Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more capital invested

Capital invested by funds: $166M → $398M (+$233M)

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

0% more funds holding

Funds holding: 39 → 39 (0)

1.04% less ownership

Funds ownership: 71.72% → 70.68% (-1%)

Holders
39
Holders Change
–
Holders Change %
0%
% of All Funds
0.77%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.08%
New
14
Increased
12
Reduced
7
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RSCM
Rock Springs Capital Management
Maryland
+$4.85M
2
BC
Boxer Capital
California
+$3.38M
3
BlackRock
BlackRock
New York
+$1.56M
4
O
OrbiMed
New York
+$760K
5
EGI
EAM Global Investors
California
+$645K

Top Sellers

1
AllianceBernstein
AllianceBernstein
Tennessee
-$11.5M
2
Millennium Management
Millennium Management
New York
-$1.1M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$513K
4
DIM
DC Investments Management
Virginia
-$457K
5
LCM
Landscape Capital Management
New Jersey
-$313K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$103M – – –
FM
2
Frazier Management
Washington
$87.5M – – –
DM
3
Deerfield Management
New York
$84.6M – – –
NHAS
4
Novo Holdings A/S
Denmark
$60M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$30.5M +$4.85M +454,952 +58%
BBA
6
Baker Bros. Advisors
New York
$8.17M – – –
BC
7
Boxer Capital
California
$7.77M +$3.38M +317,000 New
BlackRock
8
BlackRock
New York
$4.44M +$1.56M +146,114 +417%
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.97M -$15.2K -1,423 -2%
O
10
OrbiMed
New York
$1.75M +$760K +71,300 New
EGI
11
EAM Global Investors
California
$1.48M +$645K +60,509 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.44M +$400K +37,510 +178%
EI
13
EAM Investors
California
$1.15M +$499K +46,786 New
Northern Trust
14
Northern Trust
Illinois
$1.14M +$104K +9,799 +27%
WVP
15
Worth Venture Partners
New Jersey
$666K +$289K +27,148 New
Alyeska Investment Group
16
Alyeska Investment Group
Illinois
$664K -$513K -48,097 -64%
State Street
17
State Street
Massachusetts
$560K +$34.1K +3,203 +16%
Millennium Management
18
Millennium Management
New York
$546K -$1.1M -103,153 -82%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$282K +$123K +11,508 New
RJA
20
Raymond James & Associates
Florida
$217K +$94.3K +8,843 New
Morgan Stanley
21
Morgan Stanley
New York
$152K +$59.1K +5,545 +807%
Bank of America
22
Bank of America
North Carolina
$132K +$3.03K +284 +6%
UBS Group
23
UBS Group
Switzerland
$118K +$13.1K +1,229 +34%
Ensign Peak Advisors
24
Ensign Peak Advisors
Utah
$116K +$50.2K +4,706 New
JP Morgan Chase
25
JP Morgan Chase
New York
$105K +$35.7K +3,352 +362%
1
2

MIRM Hedge Fund Activity: Q4 2019 in Review

39 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q4 2019, worth a combined $398M — up 140% from $166M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new MIRM positions and 9 closed out — a net gain of 5 holders — while 12 added to existing stakes and 7 trimmed.

The largest buyer was Rock Springs Capital Management, adding an estimated $4.85M. The largest seller was AllianceBernstein, exiting entirely with an estimated $11.5M sold.

  • 39 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $398M of Mirum Pharmaceuticals stock for Q4 2019, up 140% quarter-over-quarter.
  • 14 funds opened new Mirum Pharmaceuticals positions in Q4 2019 and 9 closed out, a net change of +5 holders.
  • The largest Mirum Pharmaceuticals buyer in Q4 2019 was Rock Springs Capital Management, an estimated $4.85M added.
  • The largest Mirum Pharmaceuticals seller in Q4 2019 was AllianceBernstein, an estimated $11.5M sold.

Based on aggregated 13F filings for Q4 2019.